Author

J. Z. Wang

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Research Focus:cancer & tumor microenvironment· 3 Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:metabolism & bioenergetics· 1

Frequent Co-Authors

A. Cohen-Gadol· 1 shared A. Dayoub· 1 shared A. E. Smith· 1 shared A. Gao· 1 shared A. Gasco Hernandez· 1 shared A. Ho· 1 shared A. McCloskey· 1 shared A. S. Doane· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Cohen-Gadol

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas

J. Z. Wang, V. Patil, J. Liu, H. Dogan, F. Behling, M. Skardelly, M. Tatagiba, E. Hoffman, S. Bunda, R. Yakubov, R. Kaloti, S. Brandner, A. Gao, A. Cohen-Gadol, J. Barnholtz-Sloan, , International Consortium on Meningiomas (ICOM)

This study investigates the relationship between CDKN2A mRNA expression and clinical outcomes in meningiomas, finding that high expression is associated with poorer progression-free survival and more aggressive tumor characteristics.

Acta Neuropathologica · Jul 1, 2023Peer-reviewedCancer Biology

Tipifarnib potentiates the antitumor effects of PI3Kα inhibition in PIK3CA- and HRAS-dysregulated HNSCC via convergent inhibition of mTOR activity

A. E. Smith, S. Chan, Z. Wang, A. McCloskey, Q. Reilly, J. Z. Wang, H. V. Patel, K. Koshizuka, H. S. Soifer, L. Kessler, A. Dayoub, V. Villaflor, D. Adkins, J. Y. Bruce, A. Ho, , S. Malik

This study combines tipifarnib and alpelisib to target PI3K-mTOR and HRAS in HNSCC, showing synergy in mTOR inhibition and clinical potential for R/M HNSCC patients.

bioRxiv · Jan 17, 2023 · PreprintCancer Biology

A nuclear cAMP microdomain suppresses tumor growth by Hippo pathway inactivation

M. M. Drozdz, A. S. Doane, R. Alkallas, G. Desman, R. Bareja, M. Reilly, J. Bang, M. Yusupova, J. You, J. Z. Wang, A. Verma, K. Aguirre, E. Kane, I. R. Watson, O. Elemento, , J. H. Zippin

The paper identifies a nuclear cAMP microdomain that suppresses tumor growth by inhibiting YAP in the Hippo pathway.

bioRxiv · Nov 15, 2021Cancer Biology

Methionine synthase supports tumor tetrahydrofolate pools

J. Z. Wang, J. M. Ghergurovich, L. Yang, J. D. Rabinowitz

This study shows methionine synthase (MTR) is crucial for cells to avoid folate trapping and assimilate 5-methyl-THF into other folate species, supporting one-carbon metabolism and tumor growth.

bioRxiv · Sep 5, 2020 · PreprintCancer Biology